← Evidence map

ArticleDiabetes, obesity & metabolism2026

Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).

Aleksandrina Ruseva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE). | Socratic